Compare Illumina, Inc. (ILMN) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs iShares Core S&P 500 ETF — how do they compare? Illumina, Inc. trades at $191.86 (market cap $29.12B), while iShares Core S&P 500 ETF trades at $776.02. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | IVV | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $205.10 | $776.81 |
52-Week Low | $91.00 | $634.93 |
Enterprise Value | $30.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
